-DOCSTART- -X- O
Background. -X- _ O
Respiratory -X- _ O
syncytial -X- _ O
virus -X- _ O
( -X- _ O
RSV -X- _ O
) -X- _ O
lower -X- _ O
respiratory -X- _ O
tract -X- _ O
disease -X- _ O
( -X- _ O
LRD -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
life- -X- _ O
threatening -X- _ O
complication -X- _ O
in -X- _ O
hematopoietic -X- _ B-Patient
cell -X- _ I-Patient
transplant -X- _ I-Patient
( -X- _ I-Patient
HCT -X- _ I-Patient
) -X- _ I-Patient
recipients. -X- _ I-Patient
Lymphopenia -X- _ O
has -X- _ O
been -X- _ O
associated -X- _ O
with -X- _ O
an -X- _ O
increased -X- _ O
risk -X- _ O
of -X- _ O
progression -X- _ O
from -X- _ O
upper -X- _ O
respiratory -X- _ O
tract -X- _ O
infection -X- _ O
( -X- _ O
URI -X- _ O
) -X- _ O
to -X- _ O
LRD. -X- _ O
Methods. -X- _ O
This -X- _ O
study -X- _ O
retrospectively -X- _ O
analyzed -X- _ O
the -X- _ O
significance -X- _ O
of -X- _ O
lymphocyte -X- _ O
engraftment -X- _ O
dynamics -X- _ O
, -X- _ O
lung -X- _ O
function -X- _ O
, -X- _ O
smoking -X- _ O
history -X- _ O
, -X- _ O
corticosteroids -X- _ O
, -X- _ O
antiviral -X- _ O
treatment -X- _ O
, -X- _ O
viral -X- _ O
subtypes -X- _ O
, -X- _ O
and -X- _ O
RSV-specific -X- _ O
neutralizing -X- _ O
antibodies -X- _ O
for -X- _ O
the -X- _ O
progression -X- _ O
to -X- _ O
LRD -X- _ O
in -X- _ O
181 -X- _ B-Patient
HCT -X- _ I-Patient
recipients -X- _ I-Patient
with -X- _ I-Patient
RSV -X- _ I-Patient
URI. -X- _ I-Patient
Results. -X- _ O
In -X- _ O
multivariable -X- _ O
models -X- _ O
, -X- _ O
smoking -X- _ B-Outcome
history -X- _ I-Outcome
, -X- _ I-Outcome
conditioning -X- _ I-Outcome
with -X- _ I-Outcome
high-dose -X- _ I-Outcome
total -X- _ I-Outcome
body -X- _ I-Outcome
irradiation -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
an -X- _ I-Outcome
absolute -X- _ I-Outcome
lymphocyte -X- _ I-Outcome
count -X- _ I-Outcome
( -X- _ I-Outcome
ALC -X- _ I-Outcome
) -X- _ I-Outcome
â‰¤100 -X- _ I-Outcome
/ -X- _ I-Outcome
mm -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
at -X- _ I-Outcome
the -X- _ I-Outcome
time -X- _ I-Outcome
of -X- _ I-Outcome
URI -X- _ I-Outcome
onset -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
disease -X- _ I-Outcome
progression. -X- _ I-Outcome
No -X- _ I-Outcome
progression -X- _ I-Outcome
occurred -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
ALCs -X- _ I-Outcome
of -X- _ I-Outcome
> -X- _ I-Outcome
1000 -X- _ I-Outcome
/ -X- _ I-Outcome
mm -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
at -X- _ I-Outcome
URI -X- _ I-Outcome
onset. -X- _ I-Outcome
Lymphocyte -X- _ I-Outcome
engraftment -X- _ I-Outcome
dynamics -X- _ I-Outcome
were -X- _ I-Outcome
similar -X- _ I-Outcome
in -X- _ I-Outcome
progressors -X- _ I-Outcome
and -X- _ I-Outcome
nonprogressors. -X- _ I-Outcome
Pre- -X- _ I-Outcome
and -X- _ I-Outcome
posttransplant -X- _ I-Outcome
donor -X- _ I-Outcome
and -X- _ I-Outcome
posttransplant -X- _ I-Outcome
recipient -X- _ I-Outcome
RSV -X- _ I-Outcome
subtype-specific -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
levels -X- _ I-Outcome
, -X- _ I-Outcome
RSV -X- _ I-Outcome
viral -X- _ I-Outcome
subtypes -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
corticosteroids -X- _ I-Outcome
also -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
significantly -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
LRD -X- _ I-Outcome
progression. -X- _ I-Outcome
Conclusions. -X- _ O
Host -X- _ O
and -X- _ O
transplant -X- _ O
related -X- _ O
factors -X- _ O
appear -X- _ O
to -X- _ O
determine -X- _ O
the -X- _ O
risk -X- _ O
of -X- _ O
progression -X- _ O
to -X- _ O
LRD -X- _ O
more -X- _ O
than -X- _ O
viral -X- _ O
factors. -X- _ O
Dysfunctional -X- _ O
cell-mediated -X- _ O
immunity -X- _ O
appears -X- _ O
to -X- _ O
be -X- _ O
important -X- _ O
in -X- _ O
the -X- _ O
pathogenesis -X- _ O
of -X- _ O
progressive -X- _ O
RSV -X- _ O
disease -X- _ O
after -X- _ O
HCT. -X- _ O
A -X- _ O
characterization -X- _ O
of -X- _ O
RSV-specific -X- _ O
T-cell -X- _ O
immunity -X- _ O
is -X- _ O
warranted -X- _ O
. -X- _ O

